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Abstract 
 
Introduction 
 
Fat grafting to the breast fulfils an increased clinical demand for a 
biocompatible filler in contour refinement, volume adjustment and 
tissue rejuvenation both in cosmetic and reconstructive procedures, 
and has been used for total breast reconstruction1-5. 
 
Whilst many clinical studies have reported on the efficacy of fat 
grafting for breast cancer patients in terms of its various indications2,6-
9, technical advancements7,9-13,14, volume stability and graft 
survival5,8,9,12, 14,15-19, radiologic safety2,3,12,20-22,29,30, and complication 
rates9,12,13,23,24,25,29,30, few studies focus on oncologic safety. Fewer 
still have adequate data and follow-up period to reach meaningful 
conclusions9,19,20,26-30 .  Others report outcomes for cosmetic breast 
patients only5,24,31,32. Where oncologic safety is assessed, many 
reviews focus on radiological sequellae interfering with 
mammographic surveillance1,12,13,15,21.   
 
Meta-analyses evaluating the oncologic safety of FG have begun to 
emerge in an effort to resolve this debate with a greater sample 
size20,33-35.  However, there are limitations to the previous studies, 
particularly the consideration for confounding variables such as 
tumour histology, resection margins, receptor status and adjuvant 
treatments, which can only be corrected for by comparison with an 
appropriate control group35-37. 
 Petit et al39 reported the first case-matched retrospective series, 
(level 2b evidence).  In this study we aimed to study a large series of 
breast cancer patients treated with FG in one institution using a 
matched cohort approach, and then systematically review relevant 
published cohort studies to which our results could be compared. 
 
Method 
 
Between January 2007 and August 2013, 396 patients were treated 
with fat grafting (FG) to the breast at the Nottingham Breast Institute 
(NBI) for a variety of indications, including; breast asymmetry, contour 
deformity, correction of radiotherapy induced fibrosis and volume 
enhancement.  Excluded from this study were; benign conditions 
(68), women whose primary oncologic surgery was performed 
elsewhere with missing cancer data (51), disease recurrence prior to 
fat grafting (35), and failure to identify a suitable case control match 
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(31). Data for 211 patients (DCIS = 27, Invasive carcinoma = 184) 
treated for breast cancer between 1977 and 2013 was included.   
 
For each of the 211 FG patients included in this study, two control 
subjects were matched from a prospective database of women who 
were treated for primary breast cancer at NBI and did not undergo FG 
intervention.  Each control was matched for five variables; date of 
primary cancer operation (within 2 years), age (within 5 years), type 
of surgery, tumour histology, oestrogen receptor (ER) status and 
disease free interval by time of FG (Table 1).  Further cancer 
variables were compared between the two populations to ensure 
homogeneity (Table 2 & 3).  Similar to the Petit et al case-controlled 
series34, the selected control patient had a disease-free period 
(extrapolated  time A’-B’) at least as long as the interval between 
oncologic surgery and FG procedure (time A-B) of the corresponding 
study patient (Figure 1).  If the matched control had a recurrence prior 
to the end of this estimated time interval, then that patient was 
excluded, and another appropriate control was selected.  The primary 
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endpoint of the study was tumour recurrence, where the type and 
date were noted.  The secondary endpoint was breast cancer-related 
death. 
 
Data for women with recurrent disease prior to FG intervention (35) 
were collected for descriptive purposes and not included in the case-
matched series, but were separately analysed.  Patients treated for 
breast cancer at NBI were followed up annually with clinical 
examination and mammography for 2-5 years, depending on primary 
pathology.  
 
Figure 1. 
 
Fat grafting was performed according to the Coleman technique7,16 
without stem cell enhancement.  Tumescence included 150mg 
laevobupivicaine in 1L 0.9% Normal Saline with 1: 1 000 000 
adrenaline injected with a blunt cannula.  Donor site selection was 
dependent on surgeon and patient preference, but was most 
commonly the abdomen and upper thigh area. Fat was injected in 
thin strips. Some patients had more than one FG procedure with a 
mean of 1.28 per patient (range 1-4).   
 
A systematic literature review included all studies with adequate 
descriptions of oncologic events and follow up, reporting on patients 
treated for breast cancer with subsequent fat grafting.  Patients who 
had a recurrent event prior to FG intervention were excluded. 
  
Statistical method 
 
The difference in prognostic variables between study and control 
groups was assessed using the chi-squared test.  The main 
outcomes were recurrent oncological events in terms of local, 
regional and distant recurrences and death.  Log Rank Kaplan-Meyer 
curves were used to calculate disease free survival (DFS). 
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Any event occurring simultaneously with a local relapse, such as a 
regional recurrence or synchronous metastases, was counted as a 
single event.  In case of no events, the endpoint of the study was 
censored at the last follow-up.  Statistical significance was considered 
at a probability of p<0.05.  The impact of FG on risk of a recurrence 
was evaluated using the multivariate Cox proportion hazard 
regression model and expressed as hazard ratio (HR) with 95% 
confidence intervals (CIs). 
 
Tables 1-4 
 
 
Results 
 
Patient characteristics and follow-up are presented in Tables 1-4. The 
majority of patients in both the FG and control groups were treated by 
mastectomy; of these, almost 50% were skin sparing or nipple 
sparing mastectomies. Although the breast conserving surgery (BCS) 
Commented [RE5]: You can include figures and tables at 
the end after references 
rate in the FG group was 16.6% (35 patients), this included only one 
patient with DCIS (0.7%) (Table 3).  
 
Tables 2 & 3 show the distribution of non-matched variables in the 
FG and control groups for invasive cancer and DCIS.  The 
populations are considered well matched, with Her-2 status (p=0.013) 
and Herceptin treatment (p=0.001) being the only different variables. 
This was most likely due to a large quantity of missing data in both 
groups as a result of non-routine Her-2 testing prior to 2005. 
 
Outcome analysis 
 
The cumulative incidence of local recurrence in the FG and control 
groups was 0.95% and 1.90% respectively (p=0.744) (Tables 5&6).  
The locoregional recurrence (LRR) was equal between the FG and 
control groups (4/211, 1.9% and 8/422, 1.9%), at 0.7% per year 
(Table 6).   
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The characteristics of 4 women experiencing LRR events after the 
FG intervention are shown in Table 7.  
 
Tables 5-7, Figures 2-3 
 
Locoregional recurrence or distant metastases prior to fat grafting, 
(n=35) 
 
The mean age was of patients in this cohort was 42 years (range 27-
64) and mean follow-up after oncological surgery and fat grafting was 
170 months and 30 months respectively, with mean time to baseline 
140 months. There were 33 invasive cancers, and two cases of 
DCIS. Eleven patients (31%) initially had a mastectomy, but all 
patients eventually underwent mastectomy following  a recurrence, so 
all patient had a mastectomy prior to fat grafting.  Table 8 
demonstrates the recurrent events prior to FG in this subgroup.  
Despite 40% of these patients having a previous ipsilateral local 
recurrence, no patient suffered  further local event following FG 
procedure.  Three patients developed further non-local recurrent 
events (8.6%).  One patient developed a palpable supraclavicular 
node 20 months after the FG intervention, one patient developed a 
distant metastasis 6 months after FG and one patient developed a 
new contralateral breast cancer.   
Table 8 
 
Comparison with Case-Controlled Series in the Literature 
 
Table 9 compares this study series and the Petit34 series. There were 
a significantly greater proportion of patients undergoing BCS in the 
Petit series compared to the current series (39% v 17%). 
 
Table 9 
 
Systematic Review of Fat Grafting Case Series after Breast Cancer 
 
Tables 10a & 10b 
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Discussion  
 
The results of this study show no significant association between fat 
grafting and disease recurrence in women previously treated for 
breast cancer. This was the case both for LRR (0.7% per year for 
both FG and control groups) and distant metastases (1.2% per year 
vs 0.9% per year for FG and control groups respectively).  These 
rates are lower than those reported in the only other case-controlled 
series38, where LRR was 1.9% per year in FG, 1.7% per year in 
controls and distant metastases 1.9% per year in both groups.  This 
difference may be explained by the larger number of breast 
conserving surgery cases in their series. 
 
Fat grafting after previous breast conserving surgery for breast 
cancer may be the best model for understanding the interaction 
between the fat graft and breast parenchyma in addressing the safety 
of fat grafting37. In our series, most of the indications for fat grafting 
were in post-mastectomy patients, although half of these patients 
received a skin-sparing or nipple-sparing mastectomy. For breast 
conserving cases, the LRR was higher in the FG group compared to 
controls although not significantly so (2.1% vs 1.1% per year, p = 
0.533). In the Petit multicenter series30, comparable cumulative 
incidence curves were observed when BCS and mastectomy patients 
were analyzed separately. In their case-controlled series, Petit et al38 
reported a LRR of 2.2% per year in patients who had FG after BCS, 
which was not significantly different from controls.  
 
For the mastectomy group in our series, there was no significant 
difference in LRR amongst FG and control groups; 0.4%per year vs 
0.6% per year (p=0.848). Riggio28 reported a LRR of 0.88% per year, 
Rigotti et al26 a rate of 0.75% per year and Petit et al38 a LRR of 1.4% 
per year for FG after mastectomy (Table 11b). 
 
Unlike the Petit series30,38,39, we observed no recurrences amongst 
patients treated with FG following surgery for DCIS.  This could be 
due to a number of factors.  There was a long disease-free interval 
between primary oncologic surgery and FG in these patients (54 
months), which is the critical window period for recurrences to occur.  
This may therefore be a select low risk group, although, a relatively 
short follow-up after FG (mean 32 months) was observed. Breast 
conserving surgery for DCIS was low for both the FG and control 
arms (0.5% & 1.7% respectively), although the rate of skin-sparing 
mastectomy (SSM) was 57.6% for FG and 49.0% for the control 
arms.  In the Petit et al DCIS series39, 6 recurrences occurred in FG 
patients and 3 in controls (5 year cumulative incidence 18% & 3% 
respectively).  All recurrences in both groups had either BCS or some 
form of skin sparing mastectomy.  Furthermore, the mean time 
interval between oncologic surgery and FG in their series was 
relatively short, at 25 months, and mean time to recurrence from FG 
was 12 months. The rate of positive or close margins in the FG group 
was 42% and 22% in the controls (p 0.38) and there was no specific 
information provided regarding re-excisions or adjuvant radiotherapy 
for these patients.  Margin control and early FG intervention could be 
factors in the high LRR observed in the FG group in this series 
involving DCIS patients39.  In our series, all margins were clear. 
 
In the Petit (DCIS) series39, the likelihood of a recurrence was 
greatest if fat grafting occurred within 24 months of the primary 
oncological event. It is possible that early fat grafting may be 
associated with a greater risk of recurrence if performed in women 
with more risk factors for it. In this respect, our series may represent 
a low risk group.  Ihrai et al25 suggest a 36 month interval between 
primary surgery and fat grafting, and Riggio et al28 55 months.  The 
mean time to fat grafting in our series and Petit et al38 was similar 
(Table 10). The mean time to recurrence in the Petit DCIS series39 
was 12 months (range 5-24 months) and in the current series 50 
months for invasive cancer (range 41-58 months). 
 
There are limitations in interpreting individual studies reported in the 
literature.  They are heterogeneous, retrospective, non-matched and 
many include cosmetic breast patients without exposure to breast 
cancer.  With respect to oncologic safety, it is important to focus on 
breast cancer patients only35,36. Case-matching supports the validity 
of the results30,38.  Confounding variables such as resection margins, 
cancer histology, and receptor status can also directly influence the 
outcome.  The FG and control groups in the current study are well 
matched (Tables 1-3). 
 
However, case series may yield helpful information, if confounding 
variables are controlled for.  Table 11a&b give a summary of studies 
presenting data for patients previously treated for invasive breast 
cancer or DCIS with FG. Our review of 1573 patients reported in the 
literature shows no evidence of an increased risk of breast cancer 
recurrence following fat grafting in terms of local (0.95% per year) or 
distant metastases (1.01% per year).  Reassuringly, most series 
report both local and metastatic event rates between 1-2% per year.  
Petit et al39 found a LRR of 3.2% per year in their case-controlled 
DCIS study which increased their overall LRR.  
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Fat grafting is not a new technique, and has been exposed to 
criticism and controversy throughout its evolution5, 42-47.  In 1987, a 
position paper released by the American Society of Plastic and 
Reconstructive Surgeons (ASPRS) Ad-Hoc Committee on New 
Procedures was ‘unanimous in deploring the use of fat injection in 
breast augmentation’ as its radiological sequalae would compromise 
the detection of breast cancer on surveillance mammography48.  This 
issue has largely been resolved, as microcalcifications related to fat 
necrosis may be diagnosed after any type of breast cancer surgery 
and can be confidently distinguished from suspicious 
calcifications21,22. Despite the ‘veil of silence’ the ASPRS paper 
imposed, many surgeons were continuing to report on the use of FG 
for breast augmentation and reconstruction5-9,12,14-16,18,21,23.   Coleman 
attempted to resolve these fears, by advocating meticulous planning, 
‘atraumatic liposuction’, centrifugation and graft placement to provide 
‘pure, intact parcels of fat’ to encourage integration and long-term 
graft survival1,6,7,10,11,15,16.   He also became interested in the 
mechanisms of fat graft survival and stability, and postulated whether 
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Discussion is currently >2100 words 
 
Also the part of the biology may redundant in this clinical 
paper 
adipose-derived stems cells in the lipoaspirate may be involved, 
given their regenerative effect in experimental research and in 
‘replenishing natural tissues’7,16. Consequently, in a cautious public 
statement, both the American Society of Plastic Surgeons and 
American Society of Aesthetic Plastic Surgeons (ASPS and ASAPS) 
issued statements in 2007 that ‘strongly support the ongoing research 
efforts that will establish the safety and efficacy of the 
procedure’13,49,50. |Similarly, the French Society of Plastic, 
Reconstructive and Aesthetic Surgeons (SOFCPRE)51,52 and the UK 
NICE group54 have issued caution with regard to FG after breast 
cancer.  These societies acknowledged the lack of high level 
evidence in the literature demonstrating a link between fat grafting 
and breast cancer relapse.  Based on recent reviews, the French 
have updated their recommendations52, and a phase III multicentre 
randomized, controlled trial is currently taking place in France with 
the goal of investigating this issue54.  
 
Despite some concerns, it seems that FG is increasingly popular in 
breast surgery4,55.  In a questionnaire to UK surgeons, 69% (48/70) of 
plastic surgeons and 11% (17/158) of breast surgeons are utilizing 
the technique (Ref).  Most attitudes were positive with over 60% 
surgeons agreeing that the benefits of FG outweighed the risks. 
Similarly, the American College of Plastic Surgeons has reported 
62% of their members regularly use FG for reconstructive breast 
surgery4. 
 
Fat is a metabolically active tissue consisting of a heterogeneous cell 
population secreting cytokines, hormones and growth factors56-59.  A 
fat graft specimen contains mature adipocytes and preadipocytes, 
also known as adipose derived stem cells (ASC) 56,58,59. ASCs have 
considerable angiogenic and antiapoptotic features and constitute 
10% of the cell population, however graft survival is largely 
dependent on them given their huge proliferative contribution14,40,57-59.  
Adipocytes and ASCs release cytokines (‘adipokines’) to 
communicate with resident tissue for stimulating angiogenesis, 
reducing apoptosis, and modulating the immune response during 
tissue repair57,58,60,61.  The initial apprehension regarding FG and 
cancer resurgence came from obesity studies observing altered 
adipokine signaling in resident adipocytes that could facilitate cancer 
initiation and progression62,62.  These ‘adipokines’ have been 
extensively studied, and include; leptin, adiponectin, resistin, 
metalloproteinase 11, hepatocyte growth factor (HGF), adipocyte-
derived collagen VI, Interleukins, TGR-a, TGF-b, and VEGF57,58,60-64.  
Concern was raised that placement of these physiochemical factors 
at the site of a previous tumour microenvironment, may fuel the 
‘tumour-stromal interaction’ through autocrine, paracrine and 
exocrine/endocrine that can result in tumour recurrence14,56-61,64-66 and 
metastasis58,67,68.  The direct influence of ASCs on residual or 
dormant tumour cells has been investigated with variable results.  Co-
cultures of human epithelial and adenocarcinoma tumour cell lines 
with MSCs in murine in vitro58,67,69 and in vivo 66,68,69 models resulted 
in increased tumour cell viability, enhanced proliferation and reduced 
apoptosis of tumour cells. However, other groups found ASCs 
capable of inhibiting proliferation, down-regulating cell signalling and 
abrogating tumour progression70-72.  Zimmerman et al found that 
ASCs did not activate dormant cancer cells, but promoted residual 
active cancer cells into tumour growth and expansion.  The group 
suggested that reconstructive therapy utilizing ASC-augmented whole 
fat should be postponed until there is no evidence of active disease 
and clear margins69. 
 
Local and systemic recurrence of breast cancer is observed at similar 
rates in our case controlled series, and may occur irrespective of the 
fat grafting intervention.  Local recurrence and metastasis may be a 
manifestation of residual cancer stem cell activation and 
dissemination for reasons largely unknown, although the underlying 
molecular microenvironment may play a role56,60,73.  Long term 
dormancy of cancer cells is a known phenomenon, but it is 
particularly evident in breast cancer patients in whom, even after 8 
years of disease-free survival, a significant rate of late recurrence has 
been observed74,75.  This suggests that many cancer types can 
persist as ‘minimal residual disease’ and putative cancer stem cells 
can remain dormant for years, but are reactivated by still unknown 
mechanisms, often leading to rapid disease progression after a latent 
period76,77.  
 
The reason for the discordance between in vitro studies and clinical 
observations could be due to a number of reasons.  The initial 
question of adipocytes secreting adipokines that could fuel cancer 
cell progression came from hypertrophied resident adipocytes in 
obese patients.  This is different to the clinical setting regarding fat 
grafting, where normal adipocytes are transplanted into the breast in 
the mastectomy or prepectoral plane, and not into the parenchyma.  
In vitro and in vivo studies involve highly controlled 
microenvironments in constructed scaffolds or immunosuppressed 
animal models with many variables accounted for or eliminated.  
Furthermore, these studies have variable results with some 
adipokines stimulating cancer cell growth, and other suppressing it.  
The human subject is more complex, and there may be additional 
unrecognized pathways that abrogate adipokine signaling after fat 
grafting into a previous cancer environment in the clinical setting.   
 
As with any study, there are limitations with the current paper. This 
type of study would be difficult to design and run prospectively. The 
retrospective nature of this study is one drawback, but it facilitates 
adequate case matching. Case matching prospectively would be 
difficult due to the 5 variables requiring matching from entry into the 
study.  If either of the two control patients had a recurrence prior to 
time B’ (fat grafting intervention of the study patient), then they would 
need to be excluded, requiring that study patient also to be excluded, 
or two retrospective matches made at this point, rendering the study 
non-prospective in nature. The study is non-randomized, although 
randomization would be difficult due to the lack of a comparable 
alternative to fat grafting, and patients tend to know the benefits of 
the procedure and will ask for it, particularly if it enhances their 
reconstructive option.  The ideal candidate to study the oncological 
safety of fat grafting is in the breast conserving patient.  In our study, 
there were low numbers of patients treated with BCS – around 16% in 
each arm (35 patients in FG group), however amongst our 
mastectomy group, around half of patients received either a skin-
sparing or nipple-sparing mastectomy, with the small potential to 
leave breast tissue remaining (quote paper).  There is controversy 
surrounding FG in patients with previous DCIS, particularly those 
treated with BCS, created by the Petit et al DCIS paper39.  Our study 
cannot reliably contribute evidence to this question, as we had low 
numbers of DCIS patients treated with BCS. 
 
 
However, despite these warnings from basic science, and our study’s 
limitations, the current clinical study shows no evidence of increased 
oncological risk associated with fat grafting in women previously 
treated for breast cancer.  This evidence should be interpreted with 
other similarly case controlled studies in establishing safe indications 
for fat grafting in this setting. 
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